Core Insights - Vertex Pharmaceuticals has established itself as a leader in the cystic fibrosis (CF) market, demonstrating consistent revenue and profit growth over the past decade [1] - The company has successfully expanded its treatment portfolio beyond CF, gaining approvals for gene editing treatment Casgevy and non-opioid pain management drug Journavx [2] - Vertex's stock has seen significant appreciation, climbing over 60% in the past three years, as investor confidence has returned following successful product launches [3] Company Strengths - Vertex's ongoing strength in the CF market is a primary reason for long-term investment, with the company expected to maintain its leadership through the late 2030s due to strong intellectual property [5] - The latest CF drug, Alyftrek, has shown even greater efficacy than its previous blockbuster, Trikafta, contributing to the company's growth [5] - Vertex's drugs, Alyftrek and Trikafta, are effective for 90% of CF patients, and the company is actively working on a candidate, VX-522, to address the needs of patients who cannot take current treatments [6]